Melatonin influences pancreatic cancerogenesis

Histology and Histopathology

Volumn 29, Issue 4, 2014, Pages 423-431

  Jaworek, Jolanta ^a   Leja Szpak, Anna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiogenesis; Antioxidant enzymes; Apoptosis; Immunomodulation; Melatonin; Pancreatic cancer

Indexed keywords

ANTIOXIDANT; MELATONIN;

ANIMAL; APOPTOSIS; CARCINOGENESIS; DRUG EFFECTS; HUMAN; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARCINOGENESIS; HUMANS; MELATONIN; PANCREATIC NEOPLASMS;

EID: 84897032404     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Adamczyk-Sowa M., Sowa P., Zwirska-Korczala K., Pierzchała K., Bartosz G. and Sadowska-Bartosz I. (2013). Role of melatonin receptor MT3 and quinone reductase II in the regulation of the redox status of 3T3-L1 preadipocytes in vitro. Cell Biol. Int. 37, 835-842.
2. Adams J.M. and Cory S. (2007). Bcl-2 regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 19, 488-496.
3. Ahmed R., Mahavadi S., Al-Shboul O., Bhattacharya S., Grider J.R. and Muthry K.S. (2013). Characterization of signaling pathways coupled to melatonin receptors in gastrointestinal smooth muscle. Regul. Pept. 184, 96-103.
4. Alvarez-García V., González A., Alonso-González C., Martínez-Campa C. and Cos S. (2013) Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc. Res. 87, 25-33.
5. Autret A. and Martin S.J. (2009). Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol. Cell. 36, 355-363.
6. Beger H.G., Rau B., Gansauge F., Poch B. and Link K.H. (2003). Treatment of pancreatic cancer: challenge of the facts. World J. Surg. 27, 1075-1084.
7. Bergaminil C.M., Gambetti S., Dondi A. and Cervellaci C. (2004). Oxygen reactive species and tissue damage. Curr. Pharm. Des. 10, 1611-1626.
8. Berlin J. and Benson A.B. (2010). Chemotherapy: gemcitabine remains the standard of care for pancreatic cancer. Nat. Rev. Clin. Oncol. 7, 135-137.
9. Blask D.E. and Hill S.M. (1986). Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J. Neural Transm. Suppl. 21, 433-449.
10. Bonior J., Jaworek J., Konturek S.J. and Pawlik W.W. (2005). Increase of heat shock protein gene expression by melatonin in AR42J cells. J. Physiol. Pharmacol. 56, 471-481.
11. Bubenik G.A. (2008). Thirty years since the discovery of gastrointestinal melatonin. J. Physiol. Pharmacol. 59, 33-51.
12. Bubenik G.A, Pang S.F. and Hacker R.R. (1996). Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J. Pineal Res. 21, 251-256.
13. Cardinali D.P., Esquifino A.I., Srinivasan V. and Pandi-Perumal S.R. (2008). Melatonin and the immune system in aging. Neuroimmunomodulation 15, 272-278.
14. Carillo-Vico A. and Reiter R.J. (2006). The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs. 7, 423-431.
15. Chen C.Q., Fichna J., Bashashati M., Li Y.Y. and Storr M. (2011). Distribution, function and physiological role of melatonin in the lower gut. World J. Gastroenterol. 17, 3888-3898.
16. Chojnacki C., Wisniewska-Jarosińska M., Walecka-Kapica E., Klupińska G., Jaworek J. and Chojnacki J. (2011). Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Pharmacol. 62, 327-334.
17. Chowdhury I., Tharakan B. and Bhat G.K. (2008). Caspases an update. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 151, 10-27.
18. Cos S., Fernández R., Güézmes A. and Sánchez-Barceló E.J. (1998). Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 58, 4383-4390.
19. Cruz A., Tunez I., Martinez R., Munoz-Castaneda J.R., Ramirez L.M., Recio M., Ochoa L., Arjona A., Montilla P., Muntane J. and Padillo F.J. (2007). Melatonin prevents brain oxidative stress induced by obstructive jaundice in rats. J. Neurosci. Res. 85, 3652-3656.
20. Cui P., Yu M., Peng X., Dong L. and Yang Z. (2012). Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. J. Pineal Res. 52, 2, 236-243.
21. Curiel T.J. (2008). Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 20, 241-246.
22. Degterev A., Boyce M. and Yuan J. (2003). A decade of caspases. Oncogene 22, 8543-8567.
23. del Castillo-Vaquero A., Salido G.M. and Gonzalez A. (2010). Melatonin induces calcium release from CCK-8 and thapsigargin-sensitive cytosolic stores in pancreatic AR42J cells. J. Pineal Res. 49, 256-263.
24. DiBella L. and Gualano L. (2006). Key aspects of melatonin physiology: thirty years of research. Neuro. Endocronol. Lett. 27, 425-432.
25. Doi Y., Yashiro M., Yamada N., Amano R., Noda S. and Hirakawa K. (2012). VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann. Surg. Oncol. 19, 2733-2743.
26. Durante P., Romero F., Perez M. and Parra G. (2010). Effect of uric acid on nephrotoxicity induced by mercuric chloride in rats. Toxicol. Ind. Health 2, 163-174.
27. Ellermeier J., Wei J., Duewell P., Hoves S., Stieg M.R., Adunka T., Noerenberg D., Anders H.J., Mayr D., Poeck H., Hartmann G., Endres S. and Schnurr M. (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-ß1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 15, 73, 1709-1720.
28. Fulda S. (2009). Tumor resistance to apoptosis. Int. J. Cancer 124, 511-515.
29. Gałecka E., Mrowicka M., Malinowska M. and Gałecki P. (2008). Wolne rodniki tlenu i azotu w fizjologii. Pol. Merkur. Lek. 143, 446-448.
30. Ganguly K., Sharma A.V., Reiter R.J. and Swamakar S. (2010).Melatonin promotes angiogenesis during protection and healing of indomethacin-induced gastric ulcer: role of matrix metalloproteinase-2. J. Pineal. Res. 49, 130-140.
31. Gonzalez A., del Castillo-Vaquero A., Miro-Moran A., Tapia J.A. and Salido G.M. (2011). Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J. Pineal Res. 50, 250-260
32. Han S.S., Jang J.Y., Kim S.W., Kim W.H., Lee K.U. and Park Y.H. (2006). Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32, 271-275.
33. Hardeland R. (2008). Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol. Life Sci. 65, 2001-2018.
34. Hardeland R. and Poeggeler B. (2012). Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 12, 189-216.
35. Hardeland R., Tan D.X. and Reiter RJ. (2009). Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 42, 109-126.
36. Hess V., Salzberg M., Borner M., Morant R., Roth A.D., Ludwig C. and Herrmann R. (2003). Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J. Clin. Oncol. 1, 66-68.
37. Hinz S., Trauzold A., Boenicke C., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H. and Ungefroren H. (2000). Bcl-xL protects pancreatic adenocarcinoma cells against CD95 and TRAIL-receptor-mediated apoptosis. Oncogene 19, 5477-5486.
38. Hinz S., Pagerols-Raluy L., Oberg H.H., Ammerpohl O., Grüssel S., Sipos B., Grützmann R., Pilarsky C., Ungefroren H., Saeger H.D., Klöppel G., Kabelitz D. and Kalthoff H. (2007). Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 1, 8344-8350.
39. Hiraoka N., Onozato K., Kosuge T. and Hirohashi S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer. Res. 15, 5423-5434.
40. Homma Y., Taniguchi K., Nakazawa M., Matsuyama R., Mori R., Takeda K., Ichikawa Y., Tanaka K. and Endo I. (2013). Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin. Transl. Oncol. (in press).
41. Huang C., Huang R., Chang W., Jiang T., Huang K., Cao J., Sun X. and Qiu Z. (2012). The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 59, 52-61.
42. Huether G., Messner M., Rodenbeck A. and Hardeland R. (1998). Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J. Pineal Res. 24, 146-151.
43. Ikemoto T., Yamaguchi T., Morine Y., Imura S., Soejima Y., Fujii M., Maekawa Y., Yasutomo K. and Shimada M. (2006). Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 33, 386-390.
44. Ino Y., Yamazaki-Itoh R., Shimada K., Iwasaki M., Kosuge T., Kanai Y. and Hiraoka N. (2013). Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 108, 914-923.
45. Izawa S., Mimura K., Watanabe M., Maruyama T., Kawaguchi Y., Fujii H. and Kono K. (2013). Increased prevalence of tumor-infiltrating regulatory T cells is closely related to their lower sensitivity to H2O2-induced apoptosis in gastric and esophageal cancer. Cancer Immunol. Immunother. 62, 161-170.
46. Jaworek J., Leja-Szpak A., Bonior J., Nawrot K., Tomaszewska R., Stachura J., Sendur R. and Konturek S.J. (2003). Protective effect of melatonin and its precursor L-tryptophan on acute pancreatitis induced by caerulein overstimulation or ischemia/reperfusion. J. Pineal Res. 34, 40-52.
47. Jemal A., Siegel R., Ward E., Hao Y., Xu J.and Thun M.J. (2009). Cancer statistics. CA Cancer J. Clin. 59, 225-249.
48. Jiang P.H., Motoo Y., Sawabu N. and Minamoto T. (2006). Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J. Gastroenterol. 12, 1597-1602.
49. Kapranos N., Karaiosifidi H., Valavanis C., Kouri E. and Vasilaros S. (1997). Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res. 17, 2499-2505.
50. Kim J.S., Park Y.S., Kim J.Y., Kim Y.G., Kim Y.J., Lee H.K., Kim H.S., Hong J.T., Kim Y. and Han S.B. (2012). Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model. Immune Netw. 12, 247-252.
51. Koido S., Homma S., Takahara A., Namiki Y., Tsukinaga S., Mitobe J., Odahara S., Yukawa T., Matsudaira H., Nagatsuma K., Uchiyama K., Satoh K., Ito M., Komita H., Arakawa H., Ohkusa T., Gong J. and Tajiri H. (2011). Current immunotherapeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 267539.
52. Kossoy G., Ben-Hur H., Popovich I., Zabezhinski M., Anisimov V. and Zusman I. (2000). Melatonin and colon carcinogenesis. IV. Effect of melatonin on proliferative activity and expression of apoptosis-related proteins in the spleen of rats exposed to 1,2-dimethylhydrazine. Oncol. Rep. 7, 1401-1405.
53. Krejs G. (2010). Gastric cancer: epidemiology and risk factors. Dig. Dis. 28, 600-603.
54. Kurcer Z., Oguz E., Ozbilge H., Baba F., Aksay N. and Celik N. (2007). Melatonin protects from ischemia/reperfusion renal injury in rats: this effect is not mediated by proinflammatory cytokines. J. Pineal Res. 43, 172-178.
55. Kvetnoy I.M., Ingel I.E., Kvetnaya T.V., Malinovskaya N.K., Rapoport S.I., Raikhlin N.T., Trofimov A.V. and Yuzhakov V.V. (2002). Gastrointestinal melatonin: Cellular identification and biological role. Neuro. Endocrinol. Lett. 23, 121-132.
56. Lee W.Y., Jin Y.T. and Tzeng C.C. (1996). Reciprocal expression of Bcl2 and p53 in breast ductal carcinoma. Anticancer Res. 16, 3007-3012.
57. Leja-Szpak A., Jaworek J., Szklarczyk J., Konturek S.J. and Pawlik W.W. (2007). Melatonin stimulates HSP27 phosphorylation in human pancreatic carcinoma cells (PANC-1). J Physiol. Pharmacol. 58, 177-188.
58. Leja-Szpak A., Jaworek J., Pierzchalski P. and Reiter R.J. (2010). Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J. Pineal Res. 49, 3, 248-255.
59. Lerner A.B., Case J.D., Lee T.H. and Mori W. (1958). Isolation of melatonin, the pineal factor, that lightens melanocytes. J. Am. Chem. Sci. 80, 2587.
60. Linehan D.C. and Goedegebuure P.S. (2005). CD25+ CD4+ regulatory T-cells in cancer. Immunol. Res. 32, 155-168.
61. Lissoni P., Ardizzoia A., Barni S., Brivio F., Tisi E., Rovelli F., Tancini G., Maestroni G. and Fumagalli L. (1995). Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin a progress report of 200 patients with advanced solid neoplasms. Oncol. Rep. 2, 1063-1068.
62. Lissoni P., Fumagalli L., Paolorossi F., Rovelli F., Roselli M.G. and Maestroni G.J. (1997). Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin. J. Biol. Regul. Homeost. Agents. 11, 119-22.
63. Lissoni P., Brivio F., Fumagalli L., Messina G., Vigoré L., Parolini D., Colciago M. and Rovelli F. (2008). Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 28, 1377-1381.
64. Liu H., Xu L., Wei J.E., Xie M.R., Wang S.E. and Zhou R.X. (2011). Role of CD4+ CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat. Rec. (Hoboken). 294, 781-788.
65. Lloyd S. and Chang B.W. (2013). A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. J. Gastrointest. Oncol. 4, 123-130.
66. Lv D., Cui PL., Yao S.W., Xu Y.Q. and Yang Z.X. (2012). Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. Chin. J. Cancer Res. 24, 310-6.
67. Matsushima H., Goto T., Hosaka Y., Kitamura T. and Kawabe K. (1999). Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 85, 1822-1827.
68. Mazzoccoli G., Sothern R.B., Parrella P., Muscarella L.A., Fazio V.M., Giuliani F., Polyakova V. and Kvetnoy I.M. (2012). Comparison of circadian characteristics for cytotoxic lymphocyte subsets in nonsmall cell lung cancer patients versus controls. Clin. Exp. Med. 12, 181-194.
69. Messina G., Lissoni P., Marchiori P., Bartolacelli E., Brivio F. and Magotti L. (2010). Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients. J. Res. Med. Sci. 15, 225-228.
70. Messner M., Huether G. and Lorf T. (2001). Presence of melatonin in the human hepatobiliary tract. Life Sci. 69, 543-551.
71. Michaud D.S. (2013). Role of bacterial infections in pancreatic cancer. Carcinogenesis 34, 2193-2197.
72. Miller S.C., Pandi-Perumal S.R., Esquifino A.I., Cardinali D.P. and Maestroni G.J. (2006). The role of melatonin in immunoenhancement: potential application in cancer. Int. Exp. Pathol. 87, 81-87.
73. Miller E., Mrowicka M., Malinowska K., Kdziora J. and Majsterek I. (2011). The effect of whole body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzyme in multiple sclerosis patients. Pol. Merkur. Lek. 31, 150-153.
74. Muc-Wierzgon M., Nowakowska-Zajdel E., Zubelewicz B., Wierzgon J., Kokot T., Klakla K., Szkilnik R. and Wiczkowski A. (2003). Fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. J. Exp. Clin. Cancer Res. 22, 171-178.
75. Muilenburg D.J., Coates J.M., Virudachalam S. and Bold R.J. (2010). Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer. J. Surg. Res. 163, 276-281.
76. Mukherjee D., Roy S.G., Bandyopadhyay A., Chattopdhyay A., Basu A., Mitra E., Ghosh A.K., Reiter R.J. and Bandyopadhyay D. (2010). Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J. Pineal. Res. 48, 251-261.
77. Niess H., Conrad C., Kleespies A., Haas F., Bao Q., Jauch K.W., Graeb C. and Bruns C. (2013). Surgery for metastasis to the pancreas: is it safe and effective? J. Surg. Oncol. 107, 859-864.
78. Nio Y., Iguchi C., Yamasawa K., Sasaki S., Takamura M., Toga T., Dong M., Itakura M. and Tamura K. (2001). Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 22, 230-239.
79. Ochoa J.J., Diaz-Castro J., Kajarabille N., Garcia N., Guisado I.M., De Teresa C. and Guisado R. (2011). Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. J. Pineal Res. 51, 373-380.
80. Okumura K., Huang S. and Sinicrope F.A. (2008). Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin. Cancer Res. 14, 8132-8142.
81. Padillo F.J., Ruiz-Rabelo J.F., Cruz A., Perea M.D., Tasset I., Montilla P., Túnez I. and Muntané J. (2010). Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J. Pineal Res. 49, 3, 264-270.
82. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J., Cardinali D.P., Poeggeler B. and Hardeland R. (2006). Melatonin: nature's most versatile biological signal. FEBS J. 273, 2813-2838.
83. Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Maestroni G.J., Zisapel N. and Cardinali D.P. (2008). Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol, 85, 335-353.
84. Paredes S.D., Sanchez S., Parvez H., Rodriquez A.B. and Barriga C. (2007). Altered circadian rhythms of corticosterone, melatonin, and phagocytic activity in response to stress in rats. Neuro. Endocrinol. Lett. 11, 489-495.
85. Pino S.M., Xiong H.Q., McConkey D. and Abbruzzese J.L. (2004). Novel therapies for pancreatic adenocarcinoma. Curr. Oncol. Rep. 6, 199-206.
86. Qiu W., Sahin F., Iacobuzio-Donahue C.A., Garcia-Carracedo D., Wang W.M., Kuo C.Y., Chen D., Arking D.E., Lowy A.M., Hruban R.H., Remotti H.E. and Su G.H. (2011). Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2, 862-873.
87. Raikhlin N.T., Kvetnoy I.M. and Tolkahev V.N. (1975). Melatonin may be synthetized in enterochromaffine cells. Nature 255, 344-350.
88. Reiter R.J., Tan D.X., Manchester L.C., Pilar-Terron M., Flores L.J. and Koppisepi S. (2007). Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 52, 11-28.
89. Reiter R.J., Paredes S.D., Korkmaz A., Joum J. and Tan D.X. (2008). Melatonin combats molecular terrorism at the mitochondrial level. Interdisc. Toxicol. 1, 137-148.
90. Rodriguez M.I., Escames G., Lopez L.C., Garcia J.A., Ortiz F., Lopez A. and Acuna-Castroviejo D. (2007). Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice. J. Pineal Res. 42, 1272-1279.
91. Rosanna D.P. and Salvadore C. (2012). Reactive oxygen species, inflammation, and lung disease. Curr. Pharm. Des. 18, 3889-3900.
92. Ruiz-Rabelo J.F., Vázquez R., Perea M.D., Cruz A., González R., Romero A., Muñoz-Villanueva M.C., Túnez I., Montilla P., Muntané J. and Padillo F.J. (2007). Beneficial properties of melatonin in an experimental model of pancreatic cancer. J. Pineal Res. 43, 270-275.
93. Ruiz-Rabelo J., Vázquez R., Arjona A., Perea D., Montilla P., Túnez I., Muntané J. and Padillo J. (2011). Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. Pancreas. 40, 410-114.
94. Saif M.W., Black G., Roy S., Bell D., Russo S., Eloubeidi M.A., Steg A., Johnson M.R., Zelterman D. and Diasio R.B. (2007). Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 13, 247-256.
95. Shagirtha K., Muthumani M. and Prabu S.M. (2011). Melatonin abrogates cadmium induced oxidative stress related neurotoxicity in rats. Eur. Rev. Med. Pharmacol. Sci. 15, 1039-1050.
96. Shi C., Andersson R., Zhao X. and Wang X. (2005). Potential role of oxygen species in pancreatitis-associated multiple organ dysfunction. Pancreatology 5, 492-500.
97. Shigematsu Y., Hanagiri T., Shiota H., Kuroda K., Baba T., Ichiki Y., Yasuda M., Uramoto H., Takenoyama M., Yasumoto K. and Tanaka F. (2012). Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. Oncol. Lett. 4, 625-630.
98. Shimozuma M., Tokuyama R., Tatehara S., Umeki H., Ide S., Mishima K., Saito I. and Satomura K. (2011). Expression and cellular localization of melatonin-synthesis enzyme in rat and human salivary glands. Histochem. Cell Biol. 135, 389-396.
99. Slominski R.M., Reiter R.J., Schlabritz-Loutsevitch N., Ostrom R.S. and Slominski A.T. (2012). Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol. Cel. Endocrinol. 35, 152-166.
100. Stebelova, K., Anttila K., Manttari S., Saarela S.I. and Zeman M. (2010). Immunohistochemical definition of MT(2) receptors and melatonin in the gastrointestinal tissues of rat. Acta Histochem. 112, 26-33.
101. Stefulj J., Hortner M., Ghosh M., Schauenstein K., Rinner I., Wolfler A., Sonner J. and Liebman P.M. (2001). Gene expression of the key enzymes in melatonin synthesis in extrapineal tissues in the rat. J. Pineal Res. 30, 243-247.
102. Sun C.Y., Wang B.L., Hu C.Q., Peng R.Y., Gao Y.B., Gu Q.Y. and Wang D.W. (2002). Expression of the Bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary Pancreat. Dis. Int. 1, 306-318.
103. Takahashi H., Chen C.M., Pham H., Matsuo Y., Ishiguro H., Reber H.A., Takeyama H., Hines O.J. and Eibl G. (2013). Simultaneous knock-down of Bcl-xL nad Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Biochim. Biophys. Acta 1833, 2980-2987.
104. Tan D.X., Manchester L.C., Terran M.P., Flores L.J. and Reiter R.J. (2007). One molecule, many derivatives: a never-ending interaction of melatonin with the reactive oxygen and nitrogen species. J. Pineal. Res. 42, 28-42.
105. Tan G., Zhang X., Feng H., Luo H. and Wang Z. (2011). The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Clin. Dev. Immunol. 649359.
106. Tan D.X., Hardeland R., Manchester L.C, Korkmaz A., Ma S., Rosales-Corral S. and Reiter R.J. (2012). Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. J. Exp. Bot. 63, 577-597.
107. Tan D.X., Manchester L.C., Liu X., Rosales-Corral S.A., Acuna-Castroviejo D. and Reiter R. (2013). Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eucaryotes. J. Pineal Res. 54, 127-138.
108. Terron M.P., Delgado J., Paredes S.D., Barriga C., Reiter R.J. and Rodroguez A.B. (2009). Effect of melatonin and L-tryptophan on humoral immunity in young and old ringdoves (Streptopelia risoria). Exp. Gerontol. 44, 653-658.
109. Uguz A.C., Cig B., Espino J., Bejarano I., Naziroglu M., Rodríguez A.B. and Pariente J.A. (2012). Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J. Pineal Res. 53, 1, 91-98.
110. Vigoré L., Messina G., Brivio F., Fumagalli L., Rovelli F., DI Fede G. and Lissoni P. (2010). Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin. In Vivo 24, 787-789.
111. Wu H., Chen P., Liao R., Li Y.W., Yi Y., Wang J.X., Cai X.Y., He H.W., Jin J.J., Cheng Y.F., Fan J., Sun J. and Qiu S.J. (2013). Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients. J. Gastroenterol. Hepatol. 28, 1555-1564.
112. Xu Z.W., Friess H., Büchler M.W. and Solioz M. (2002). Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol. 49, 504-510.
113. Xu C., Wu A., Zhu H., Fang H., Xu L., Ye J. and Shen J. (2013). Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Biomed. Pharmacother. 67, 133-139.
114. Yamamoto T., Yanagimoto H., Satoi S., Toyokawa H., Hirooka S., Yamaki S., Yui R., Yamao J., Kim S. and Kwon A.H. (2012). Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas. 41, 409-415.
115. Yang F.L., Soberg M.Y., Lee C.J., Lee RP., Peng T.C. and Hsu B.G. (2011). Melatonin ameliorates hemorrhagic shock-induced organ damage in rats. J. Surg. Res. 167,15-21.
116. Zavoral M., Minarikova P., Zavada F., Salek C. and Minarik M. (2011). Molecular biology of pancreatic cancer. World J. Gastroenterol. 28, 17, 2897-2908.
117. Zawilska J.B., Skene D.J. and Arendt J. (2009). Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep. 61, 383-410.
118. Zhao F., Obermann S., von Wasielewski R., Haile L., Manns M.P., Korangy F. and Greten TF. (2009). Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128, 1141-149.
119. Zhou W., Wang P. and Tao L. (2009). Effect of melatonin on proliferation of neonatal cord blond mononuclear cells. World J. Pediatr. 5, 300-303.